Loading
Disease Models, Animal / Staphylococcal Infections · Journal article
Emerging Microbes & Infections · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study demonstrating that an experimentally evolved phage K variant (KJ25) shows enhanced in vitro and ex vivo killing of MRSA USA300 with preserved lung tissue integrity. The work is exploratory and raises the hypothesis that phage adaptation may enhance therapeutic efficacy, but lacks in vivo efficacy data, animal infection models, and any clinical translation.
Experimental evolution study with in vitro and ex vivo comparative evaluation. Staphylococcus aureus USA300 (community-associated MRSA); no animal or human subjects enrolled. Intervention: Evolved phage KJ25 (derivative of phage K with function-impairing mutation in gene gp102). Compared with: Wild-type phage K.
Phage KJ25 achieved faster bacterial reduction and sustained suppression of regrowth compared to wild-type phage K in growth inhibition assays KJ25 infection induced slower and less disruptive host transcriptional takeover than wild-type phage K In both A549 lung epithelial cells and murine precision-cut lung slices, phage KJ25 markedly reduced bacterial burden while preserving lung tissue integrity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is mechanistic and exploratory rather than clinically actionable. It suggests a potential strategy for phage engineering but requires in vivo efficacy data in animal pneumonia models and eventual clinical testing before informing therapeutic development.
Experimental evolution study using in vitro and ex vivo models to characterize an adapted phage variant; no animal infection efficacy data, clinical outcomes, or in vivo proof of concept reported.
As stated by the source record.
This work is mechanistic and exploratory rather than clinically actionable. It suggests a potential strategy for phage engineering but requires in vivo efficacy data in animal pneumonia models and eventual clinical testing before informing therapeutic development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Hypervirulent community-associated MRSA clones such as Staphylococcus aureus (S. aureus) USA300 drive rapidly progressive necrotizing pneumonia with high morbidity and limited therapeutic options. Bacteriophage K (phage K) is a well-characterized lytic phage active against S. aureus, but its efficacy is limited by restricted host range and the emergence of bacterial resistance. Here, we subjected phage K to experimental evolution on S. aureus USA300 to select an adapted variant with enhanced bactericidal properties. Wild-type phage K and the evolved derivative, designated phage KJ25, were compared using growth inhibition assays, time-kill kinetics, genomic differences and transcriptomic analyses of the bacterial response to infection. Efficacy was evaluated in an in vitro A549 lung epithelial cell infection model and ex vivo murine precision-cut lung slices (PCLS). Phage KJ25 exhibited significantly improved killing of USA300, achieving faster bacterial reduction and sustained suppression of regrowth. Genomic analysis identified a function-impairing mutation in gene gp102, encoding a predicted DNA-binding protein implicated in transcriptional regulation. RNA sequencing revealed that KJ25 infection of USA300 induced a slower and less disruptive host transcriptional takeover than wild-type phage K. Importantly, in both A549 cells and PCLS model, phage KJ25 markedly reduced bacterial burden while preserving lung tissue integrity, supporting its therapeutic potential. Collectively, these findings highlight the value of experimental evolution for tailoring therapeutic phages and support phage adaptation as a promising strategy for developing interventions against multidrug-resistant S. aureus.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.